AFT Pharmaceuticals - Maxigesic IV hits a roadblock in the US
In an unexpected development, AFT Pharmaceuticals (AFT) has announced that it has received a complete response letter (CRL) from the United States...
674 Views
AFT Pharmaceuticals - Re-acceleration leveraging its platform
Overcoming COVID-19 headwinds, AFT Pharmaceuticals reported strong FY22 year results, largely driven by management’s ability to leverage its broad...
680 Views
AFT Pharmaceuticals - Recovery driven by strong H222
AFT Pharmaceuticals (AFT) reported FY22 revenue of NZ$130.3m, up from NZ$113.1m in FY21, driven by improved performance in H222 (versus H122) amid...
672 Views
AFT Pharmaceuticals: 1H22 Result — A Bump in the Road
AFT Pharmaceuticals1H22 Result — A Bump in the Road RESEARCH INSIGHTS AFT Pharmaceuticals (AFT) reported a lower than expected underlying 1H22...
802 Views
AFT Pharmaceuticals (AFT): 1H22 Result – Initial Impressions
AFT Pharmaceuticals (AFT)1H22 Result – Initial Impressions AFT Pharmaceuticals (AFT) reported a 1H22 result below expectations, but significantly...
772 Views